GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » M3 Inc (TSE:2413) » Definitions » COGS-to-Revenue

M3 (TSE:2413) COGS-to-Revenue : 0.40 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is M3 COGS-to-Revenue?

M3's Cost of Goods Sold for the three months ended in Dec. 2023 was 円25,354 Mil. Its Revenue for the three months ended in Dec. 2023 was 円63,394 Mil.

M3's COGS to Revenue for the three months ended in Dec. 2023 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. M3's Gross Margin % for the three months ended in Dec. 2023 was 60.01%.


M3 COGS-to-Revenue Historical Data

The historical data trend for M3's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

M3 COGS-to-Revenue Chart

M3 Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.44 0.39 0.41 0.41

M3 Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.42 0.40 0.41 0.40

M3 COGS-to-Revenue Calculation

M3's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=95632 / 230818
=0.41

M3's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=25354 / 63394
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


M3  (TSE:2413) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

M3's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 25354 / 63394
=60.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


M3 COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of M3's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


M3 (TSE:2413) Business Description

Traded in Other Exchanges
Address
Akasaka Intercity 10th floor, 1-11-44 Akasaka, Minato-ku, Tokyo, JPN, 105-0012
M3, Inc. is a Japan-based company engaged in providing medical-related services through the use of the Internet. It also supports marketing of pharmaceutical companies and medical equipment manufacturers. The company's business segment includes, Medical Portal segment, Evidence Solution segment, Overseas segment, Clinical Platform segment, Sales Platform segment, and Others. The company generates the majority of its revenue from Medical Portal segment.

M3 (TSE:2413) Headlines

No Headlines